Other Phase 3 studies (The ALPS, ANDES, and OLYMPUS studies) showed that roxadustat was more effective in achieving and maintaining target Hb levels compared with placebo in NDD-CKD patients [64,65,66]. Here, GSTM1 is linked to chronic kidney disease.